63673-72-3

Upstream product

• 125968-55-0 2-amino-4,6-bis(p-methoxyphenyl)pyrimidine 
• 41564-67-4 (E)-1,3-bis(4-methoxyphenyl)-2-propene-1-one 
• 24030-15-7 4,6-bis(4-methoxyphenyl)pyrimidin-2-ol 
• 123-11-5 4-methoxy-benzaldehyde 
• 1228151-43-6 4,6-bis(4-methoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 5720-07-0 4-methoxyphenylboronic acid 

Downstream Products

• 163263-89-6 C₂₄H₂₀N₂O₄ 
• 1048694-37-6 2-methoxy-4,6-bis(4-methoxyphenyl)pyrimidine 

Relevant academic research and scientific papers

Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors

Presently, artemisinin-based combination therapy (ACT) is the first-line therapy of Plasmodium falciparum malaria. With the emergence of malaria parasites that are resistant to ACT, alternative antimalarial therapies are urgently needed. In line with this

Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy

Duchenne muscular dystrophy is a fatal disease with no cure, caused by lack of the cytoskeletal protein dystrophin. Upregulation of utrophin, a dystrophin paralogue, offers a potential therapy independent of mutation type. The failure of first-in-class utrophin modulator ezutromid/SMT C1100 in Phase II clinical trials necessitates development of compounds with better efficacy, physicochemical and ADME properties and/or complementary mechanisms. We have discovered and performed a preliminary optimisation of a novel class of utrophin modulators using an improved phenotypic screen, where reporter expression is derived from the full genomic context of the utrophin promoter. We further demonstrate through target deconvolution studies, including expression analysis and chemical proteomics, that this compound series operates via a novel mechanism of action, distinct from that of ezutromid.

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents

Breast cancer is the most frequently diagnosed cancers and the leading causes of cancer death among females worldwide. Estrogen receptor positive has been identified as the predominant internal reasons, involving in more than 70% breast cancer patients and SERMs which competes with estradiol for the binding to ERα in breast tissue are widely used in the treatment of ER+ breast cancer, such as tamoxifen, raloxifene. However, many SERMs may cause negative side effects due to their estrogenic activity in other tissues and approximate 50% of patients with ER-positive tumors either initially do not respond or become resistant to these drugs. Here, a series of designed 4,6-diaryl-2-pyrimidinamine derivatives had been synthesized to treat estrogen receptor positive breast cancer by simultaneously antagonizing ER and inhibiting VEGFR-2. Bioactivity evaluation showed that these compounds could significantly inhibit the proliferation of MCF-7, HUVEC and Ishikawa cells. Further studies identified compound III-3A could antagonize against estrogen action and inhibit the phosphorylation of VEGFR-2 as well as inhibit angiogenesis in vivo. The results indicated designed 4,6-diaryl-2-pyrimidinamine derivatives can be used to further study as anti-breast cancer drugs.

4,6-dibenzyl pyrimidine compounds, preparing method thereof and medical uses of the compounds

The invention relates to the field of pharmaceutical chemistry, and specifically relates to 4,6-dibenzyl pyrimidine compounds shown as a general formula I or a general formula II. The compounds can be adopted as selective estrogen receptor modulators, can be used for treating or preventing a plurality of medical indications related to postmenopausal symptoms, and is particularly suitable for treatment of ER-(+) type breast carcinoma. In addition, the compounds can be used for preparing angiogenesis inhibitor medicines.

Star- and banana-shaped oligomers with a pyrimidine core: Synthesis and light-emitting properties

By using Suzuki-Miyaura cross-coupling reactions we have synthesised a series of star- and banana-shaped oligomers with a pyrimidine unit as the central core and π-conjugated arms consisting of aromatics bearing electron-donor substituents. The position of the arms as well as the nature of their substituents were investigated with a view to accessing compounds that exhibit interesting light-emitting properties. The best fluorescence quantum yields were obtained with banana-shaped pyrimidines substituted with p-(dimethyl-amino)phenyl or 2-furyl groups. Comparison of the optical properties of oligomers with benzene, pyrimidine or s-triazine as the central unit revealed that the pyrimidinic compounds gave the best results. Some of the oligomers synthesised exhibit solvatochromic properties and pH sensibility, which could allow their use as polarity or pH sensors. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Coating compositions stabilized against damage by light, heat and oxygen

Coatings comprisingA) a binder based on an organic polymer andB) as stabilizer against damage by light, heat and oxygen, a 2-(2′-hydroxyphenyl)-1,3-pyrimidine of the formula I ?in which the radicals R1 to R6 are as defined in claim 1 have an outstanding resistance to the damaging effects of light, oxygen and heat. Compounds of the formula Ib defined in claim 18 are suitable in general for the stabilization of organic material.